TriangleEpcoritamab + Ibrutinib (NCT06536049)
Epcoritamab + Ibrutinib trial for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT06536049). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with aggressive B cell non-Hodgkin lymphoma, such as diffuse large B cell lymphoma, that has come back or not responded to treatment.
The idea: combine epcoritamab and ibrutinib. Epcoritamab is a bispecific antibody, given as a shot under the skin, that binds CD3 on T cells and CD20 on lymphoma cells at the same time, bringing them together. Ibrutinib is a daily pill.
The study looks at safety, the best dose, and how well it works.
This phase 1 and 2 study plans 38 patients. At Ohio State University Comprehensive Cancer Center in Columbus, Yazeed Sawalha leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.